

Appointment of Independent Financial Adviser for Strategic Review

Sydney, Australia, 1 July 2026: Chimeric Therapeutics (ASX: CHM) (**Chimeric** or the **Company**), a leading Australian cell therapy company, advises that it has appointed Hawkesbury Partners Pty Limited (**Hawkesbury Partners**) as its Independent Financial Adviser to undertake a review of strategic options available to the Company with the objective of maximising shareholder value.

Key Points

- The Board is actively reviewing all strategic and funding options with the objective of maximising shareholder value
- Hawkesbury Partners appointed Independent Financial Adviser to support the strategic review and identify and evaluate opportunities to monetise and realise value for Chimeric.

Strategic Review

The Board has determined that a structured, adviser-led review of Chimeric's strategic options is in the best interests of shareholders. Chimeric has invested over A\$80 million in building its clinical programmes and the manufacturing, quality, and regulatory infrastructure that underpins them. The Board believes the value embedded in this portfolio is not currently reflected in the Company's market capitalisation.

Hawkesbury Partners' mandate is to identify and evaluate opportunities to realise and maximise the value of Chimeric and its assets for the benefit of shareholders. This may include strategic partnerships and funding, licensing arrangements, co-development agreements, mergers, asset sale transactions, and alternative capital structures.

Hawkesbury Partners is a corporate and capital markets advisory firm which provides capital raising, M&A and strategic advisory services with deep expertise supporting life sciences companies. Hawkesbury Partners holds Australian Financial Services Licence 432 322 and has confirmed to the Board that it is independent and conflict free for the purposes of this engagement.

There is no certainty any transaction will result from this process and Chimeric will update the market on material developments as they arise, consistent with its continuous disclosure obligations.

Authorised on behalf of the Chimeric Therapeutics by the Board of Directors.



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

For more information visit www.chimerictherapeutics.com or follow us on LinkedIn at www.linkedin.com/company/chimeric-therapeutics.

For more information:

Corporate Enquiries

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

Email: investors@chimerictherapeutics.com

Investor & Partnering Enquiries

David Allen, John Granger and Sam Robinson

Hawkesbury Partners

Email: investors@chimerictherapeutics.com